Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | NEOS: prognosis of ER+ breast cancer pts who received neoadjuvant ET with/without adjuvant chemo

Hiroji Iwata, MD, PhD, Aichi Cancer Center Hospital, Nagoya, Japan, presents the primary analysis from the NEOS trial, a randomized Phase III study that assessed the long-term prognosis of patients with estrogen receptor-positive (ER+) primary breast cancer who received neoadjuvant endocrine therapy with or without adjuvant chemotherapy. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.